Shares of Septerna Inc. (SEPN) are up over 65% at $11 in premarket trading Wednesday, after the company announced an exclusive global partnership with Novo Nordisk (NVO). The deal focuses on developing oral small-molecule drugs to treat obesity, type 2 diabetes, and other heart-related metabolic conditions.
Septerna specializes in creating drugs that target G protein-coupled receptors (GPCRs), using its unique Native Complex Platform. As part of the agreement, the two companies will start with four drug development programs aimed at specific GPCR targets, including GLP-1, GIP, and glucagon receptors.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.